Discovery of a Dual PRMT5–PRMT7 Inhibitor

Citations Over TimeTop 10% of 2015 papers

Abstract

The protein arginine methyltransferases PRMT7 and PRMT5, respectively, monomethylate and symmetrically dimethylate arginine side-chains of proteins involved in diverse cellular mechanisms, including chromatin-mediated control of gene transcription, splicing, and the RAS to ERK transduction cascade. It is believed that PRMT5 and PRMT7 act in conjunction to methylate their substrates, and genetic deletions support the notion that these enzymes derepress cell proliferation and migration in cancer. Using available structures of PRMT5, we designed DS-437, a PRMT5 inhibitor with an IC50 value of 6 μM against both PRMT5 and PRMT7 that is inactive against 29 other human protein-, DNA-, and RNA-methyltransferases and inhibits symmetrical dimethylation of PRMT5 substrates in cells. This compound behaves as a cofactor competitor and represents a valid scaffold to interrogate the potential of the PRMT5-PRMT7 axis as a target for therapy.

Related Papers

• → The Protein Arginine Methyltransferases 1 and 5 affect Myc properties in glioblastoma stem cells(2019)41 cited
• → Methylation of phytohormones by the SABATH methyltransferases(2010)17 cited
• → SMYD4 monomethylates PRMT5 and forms a positive feedback loop to promote hepatocellular carcinoma progression(2024)9 cited
• → An Abnormal Methylation Ratio Induces Hypomethylation In Vitro in the Brain of Pig and Man, But Not in Rat(1995)32 cited
• → The Protein Arginine Methyltransferases 1 and 5 affect Myc properties in glioblastoma stem cells.(2019)